Cancer Biomarkers
Scope & Guideline
Advancing the Science of Cancer Biomarkers.
Introduction
Aims and Scopes
- Biomarker Discovery and Validation:
The journal extensively publishes research aimed at discovering novel biomarkers that can be used for early detection, diagnosis, and prognosis of different cancer types. - Molecular Mechanisms of Cancer:
Research articles often focus on elucidating the molecular pathways and mechanisms through which identified biomarkers influence cancer progression and response to therapies. - Genomic and Epigenomic Studies:
A significant focus is placed on genomic and epigenomic alterations in cancer, including DNA methylation patterns and gene expression profiles that correlate with clinical outcomes. - Machine Learning and Bioinformatics:
The journal supports the application of machine learning and bioinformatics tools to analyze complex datasets and identify biomarkers with clinical relevance. - Immune Biomarkers and Microenvironment:
Research exploring the role of immune-related biomarkers and the tumor microenvironment in cancer progression and treatment response is a key area of focus.
Trending and Emerging
- Long Non-Coding RNAs (lncRNAs):
Research on lncRNAs is rapidly increasing, highlighting their potential roles as biomarkers for various cancers, particularly in regulating gene expression and cancer progression. - Immune Checkpoint Inhibitors:
The exploration of biomarkers related to immune checkpoint inhibitors is trending, reflecting the rise of immunotherapy as a cornerstone in cancer treatment. - Multi-Omics Approaches:
There is a growing trend towards multi-omics studies, integrating genomic, transcriptomic, proteomic, and metabolomic data to provide comprehensive insights into cancer biology and biomarker discovery. - Artificial Intelligence in Biomarker Discovery:
The use of AI and machine learning algorithms to analyze complex datasets and improve biomarker identification and validation is an emerging theme, indicating a shift towards data-driven research methodologies. - Tumor Microenvironment Studies:
Research focusing on the tumor microenvironment and its impact on cancer progression and therapy response is gaining prominence, emphasizing the interplay between cancer cells and their surrounding environment.
Declining or Waning
- Traditional Tumor Markers:
Research focusing on conventional tumor markers such as CEA or CA 19-9 appears to be declining as novel biomarkers and more sophisticated molecular techniques gain prominence. - Single Biomarker Studies:
There has been a shift away from studies focusing solely on single biomarkers, as the field moves towards multi-biomarker panels and integrative approaches that consider the complexity of cancer biology. - Invasive Diagnostic Techniques:
Research on invasive diagnostic methods is waning in favor of non-invasive liquid biopsy techniques that utilize circulating biomarkers for cancer detection and monitoring. - Chemotherapy Response Predictors:
The exploration of predictive biomarkers specifically for chemotherapy response has decreased, likely due to a broader focus on immunotherapy and targeted therapies. - Non-specific Biomarkers:
Interest in non-specific biomarkers that lack clear associations with particular cancer types or outcomes has diminished as the field emphasizes more precise and context-specific biomarker identification.
Similar Journals
Cancer Genomics & Proteomics
Exploring the genetic and protein landscapes of cancer.Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Exploring the Frontiers of Genetic MutationMUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.
Molecular & Cellular Oncology
Unraveling the complexities of cancer biology.Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.
Cancer Communications
Unlocking Insights in Oncology for AllCancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.
Journal of Cancer Metastasis and Treatment
Advancing oncology through innovative research.Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.
MOLECULAR CARCINOGENESIS
Exploring the Frontiers of Cancer ResearchMOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Fostering collaboration for groundbreaking cancer discoveries.The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.
MOLECULAR CANCER RESEARCH
Unveiling Molecular Insights in OncologyMOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.
JOURNAL OF GENE MEDICINE
Empowering the Next Generation of Molecular MedicineThe Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.
Analytical Cellular Pathology
Advancing the Frontiers of Cellular InsightsAnalytical Cellular Pathology, published by Hindawi Ltd, is a leading journal in the disciplines of Cancer Research, Cell Biology, and Pathology, and has been dedicated to advancing the field through open access since 1997. Based in Egypt, this journal plays a crucial role in disseminating cutting-edge research and innovative findings, fostering collaboration among researchers and professionals alike. With an impressive array of metrics, including its Q2 ranking in Pathology and Forensic Medicine and notable Scopus rankings, the journal attracts a diverse readership, ensuring significant impact in its categories. Designed to cater to the needs of both emerging and established scholars, Analytical Cellular Pathology promotes accessibility and exchange of knowledge, making it an indispensable resource for those engaged in modern cellular pathology research.